Literature DB >> 267281

Portal hypertension in a patient with chronic myeloid leukaemia.

M D Foadi, S Shaw, F J Paradinas.   

Abstract

A patient with chronic myeloid leukaemia treated with busulphan for 4-5 years, developed signs of busulphan toxicity and portal hypertension with ascites, oesophageal varices and jaundice. At post-mortem there was minimal leukaemic infiltration but there were alterations in the liver architecture sufficient to explain the portal hypertension. The pathogenesis of the liver changes and their possible relationship to splenomegaly and busulphan toxicity are considered.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 267281      PMCID: PMC2496554          DOI: 10.1136/pgmj.53.619.267

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  3 in total

1.  Spleen blood flow and splanchnic haemodynamics in blood dyscrasia and other splenomegalies.

Authors:  L M Blendis; D C Banks; C Ramboer; R Williams
Journal:  Clin Sci       Date:  1970-01       Impact factor: 6.124

2.  Liver in Felty's syndrome.

Authors:  L M Blendis; I D Ansell; K L Jones; E Hamilton; R Williams
Journal:  Br Med J       Date:  1970-01-17

3.  Portal hypertension in chronic leukaemia.

Authors:  D V Datta; S L Grover; V K Saini; B N Datta; B K Aikat; P N Chhuttani
Journal:  Br J Haematol       Date:  1975-11       Impact factor: 6.998

  3 in total
  1 in total

1.  Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia?

Authors:  L Lennard; H A Davies; J S Lilleyman
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.